02170 BASECARE-B
- 2.400
- -0.050-2.04%
BASECARE-B News
Express News | CITIC Construction Investment: The national biotechnology and biomanfacture action plan is expected to be introduced in the near future, and the subsequent implementation of the policy is worth looking forward to
Hong Kong stock changes丨Beikang Healthcare and Jinxin Fertility both surged more than 8%, and Jiangxi Province included 9 assisted reproductive technologies in medical insurance reimbursement
Glonghui, May 13 | Assisted Reproduction concept stocks in the Hong Kong stock market strengthened collectively. Among them, Jinxin Fertility once rose more than 9%, and Beckham Medical-B rose more than 8%. According to the news, starting on June 1, the “Jiangxi Provincial Health Insurance and Medical Service Project Payment Management Catalogue (2024)” was officially implemented. Nine assisted reproduction programs, including “egg retrieval” and “artificial insemination,” are included in the scope of provincial medical insurance payments, which means that insured people in Jiangxi Province can also be covered by medical insurance reimbursement for IVF! Since 2023, some provinces in China have included assisted reproduction in medical insurance reimbursement to solve the problem of “not being able to give birth and are afraid to give birth” and help families who wish to have children
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
貝康醫療-B：年度報告2023
Beacon Healthcare (2170.HK): Revenue and gross profit both increased by 50%, major acquisitions helped build the Chinese version of Vitrolife
Since Beijing first included 16 assisted reproduction programs in health insurance in June of last year, under the impetus of the National Health Insurance Administration, Guangxi, Inner Mongolia, Gansu and other places have followed suit and included some assisted reproduction programs in medical insurance, including egg retrieval, embryo culture, embryo transfer, sperm selection, diagnosis of embryonic genetic diseases (PGT-M), pre-implantation embryonic genetic testing (PGT-SR) for chromosomal diseases, and cell freezing. The overall reimbursement rate for these projects is as high as 50%-70%, and some projects can even be reimbursed twice.
BASECARE MEDICAL-B (02170. HK) Announces Annual Performance: Revenue and Gross Profit Growth of 48% and 53%, Completing Acquisition of BMX to Accelerate Globalization Layout
Basecare Medical-B (02170. HK) announced its annual performance. As of December 31, 2023, the group's revenue was RMB 208 million, a year-on-year increase of approximately 48%; The gross profit was RM
Beckon Medical-B (02170.HK) announced annual results: gross profit increased 48% and 53% year over year, completed the acquisition of Singapore BMX to accelerate global layout
Gelonghui, March 29丨Beacon Medical-B (02170.HK) announced its annual results. For the year ended December 31, 2023, the Group's revenue was RMB 208 million, up about 48% year on year; gross profit was RMB 91.351 million, up about 53% year on year; the Group's overall gross margin was 43.9%, which is basically the same as 42.2% for the year ended December 31, 2022. The increase in revenue was mainly due to (i) the steady increase in sales of PGT kits, (ii) the increase in sales of ultra-low temperature storage equipment and smart liquid nitrogen tanks; and (iii) embryo incubators and
Beckon Medical-B (02170) announces 2023 results, shareholders' equity losses of about 192 million yuan, an increase of 56.27% year-on-year
According to the Zhitong Finance App, Beacon Medical-B (02170) announced its 2023 results, with revenue of about 208 million yuan, up 47.6% year on year; loss attributable to the company's equity shareholders was about 192 million yuan, an increase of 56.27% year on year; loss per share was 0.7 yuan. According to the announcement, the increase in revenue was mainly due to the steady increase in sales of PGT kits, the increase in sales of ultra-low temperature storage equipment and smart liquid nitrogen tanks; and the increase in revenue from sales of consumables such as embryo incubators and culture medium.
BASECARE-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Beacon Medical-B (02170.HK) will hold a board meeting on March 28 to approve the full year results
Gelonghui, March 18 | Beckon Medical-B (02170.HK) announced that the company will hold a board meeting on March 28, 2024 to adopt the annual results of the company and its subsidiaries for the year ended 31 December 2023 and consider the payment of a final dividend (if any).
貝康醫療-B：董事會會議通告
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
A quick overview of the Hong Kong market | The Hang Seng Index rose nearly 2%, and the Science Index rose nearly 3%; insurance, real estate and other sectors were strong throughout the day
Technet stocks were strong. Meituan rose nearly 5%, Bilibili and Kuaishou rose more than 3%, Xiaomi and Jingdong rose more than 2%, Baidu, Ali, and Tencent rose more than 1%, and NetEase followed; insurance stocks were strong throughout the day. China Ping An rose more than 6%, China Life Insurance rose nearly 5%, and AIA Insurance rose more than 2%.
Intraday Overview | The three major indices rose slightly, and the Tech Index rose nearly 2%; auto stocks and biotech stocks rose strongly. NIO rose nearly 8%, and Pharmaceutical Biotech rose more than 9%
Most Technology Network stocks rose, with Station B up more than 4%; Meituan and NetEase up more than 3%; mobile phone equipment stocks showed active performance, with Shunyu Optical Technology up more than 7% and Gaowei Electronics by more than 5%; pharmaceutical distribution stocks improved, Ali Health rose more than 8%, and JD Health rose nearly 5%.
Intraday Overview | The Tech Index fell more than 2%, Apple concept stocks and pharmaceutical stocks had the highest declines, and Shunyu Optical Technology fell more than 8%
Technet stocks collectively weakened, with Xiaomi falling nearly 4%, Meituan falling nearly 3%, and Kuaishou falling more than 2%; domestic housing stocks continued to decline, with Country Garden falling more than 3%; Longhu Group, Xincheng Development, and Sunac China falling nearly 2%; auto stocks were weak, with Zero Sports Auto and NIO falling more than 5%, and Xiaopeng Motors falling more than 4%.
In-depth layout of “AI+ Healthcare”, Beckon Healthcare (02170.HK) leads the wave of smart medical care
In recent years, with the continuous advancement of technology, the application of artificial intelligence (AI) in the medical field is showing unlimited potential. In an age where population issues are prominent, the combination of artificial intelligence and medical treatment may become a “good medicine” to alleviate the shortage of medical resources in our country.
Innovative drugs, the standard-bearer of the Hong Kong stock market
However, the protagonist leading the rebound of A/H shares in this round is innovative pharmaceuticals+consumer electronics. Judging from the past half month, consumer electronics has performed better in A-shares, while innovative drugs have performed more fiercely in Hong Kong stocks.
Intraday quick overview | The three major indices rushed higher and fell, and the index rose slightly; pharmaceutical stocks and domestic housing stocks had the highest gains, Pharmaceuticals Biotech rose more than 5%, and Country Garden rose more than 4%
Most of the Internet of Technology stocks rose, Kuaishou and Tencent rose nearly 2%; most auto stocks fell; Xiaopeng Motor fell by more than 4%, and Zero Sports fell by more than 3%.
Can we expect a large-scale market? Pharmaceutical funds have rebounded across the board. What I'm most concerned about is actually...
What pharmaceutical fund managers are most worried about now is whether non-pharmaceutical funds and top players will think about it again in the midst of a ferocious pharmaceutical backlash.
Analysis
Price Target
No Data
